The 4717C > G polymorphism in periplakin modulates sensitivity to EGFR inhibitors

• Main Authors: Lee, Hui Mei, Kelly, Gregory Michael, Zainal, Nur Syafinaz, Yee, Pei San, Fadlullah, Muhammad Zaki Hidayatullah, Lee, Bernard Kok Bang, Gan, Chai Phei, Patel, Vyomesh, Cheong, Sok Ching
• Format: Article
• Language: English
• Published: Nature Research 2019
• Subjects: R Medicine; RK Dentistry
• Online Access: http://eprints.um.edu.my/23887/1/s41598-019-38742-0.pdf; http://eprints.um.edu.my/23887/; https://www.nature.com/articles/s41598-019-38742-0.pdf

The use of EGFR inhibitors on oral squamous cell carcinoma (OSCC) as monotherapy yielded modest clinical outcomes and therefore would benefit from biomarkers that could predict which patient subsets are likely to respond. Here, we determined the efficacy of erlotinib in OSCC cell lines, and by comparing sensitive and resistant lines to identify potential biomarkers. We focused on the 4717C > G polymorphism in periplakin (PPL) where the CC genotype was associated with erlotinib resistance. To validate this, erlotinib-resistant cell lines harbouring CC genotype were engineered to overexpress the GG genotype and vice versa. Isogenic cell lines were then studied for their response to erlotinib treatment. We demonstrated that overexpression of the GG genotype in erlotinib-resistant lines sensitized them to erlotinib and inhibition of AKT phosphorylation. Similarly, the expression of the CC genotype conferred resistance to erlotinib with a concomitant increase in AKT phosphorylation. We also demonstrated that cell lines with the CC genotype generally are more resistant to other EGFR inhibitors than those with the GG genotype. Overall, we showed that a specific polymorphism in the PPL gene could confer resistance to erlotinib and other EGFR inhibitors and further work to evaluate these as biomarkers of response is warranted.